Company
Headquarters: Sao Paulo, SP, Brazil
Employees: 94
CEO: Mr. Heraldo Marchezini
R$974.3 Million
BRL as of Jan. 1, 2026
US$177.3 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in São Paulo, Brazil.
Biomm SA has the following listings and related stock indices.
Stock: Bovespa: BIOM3